Pulmatrix Inc. PULM (U.S.: Nasdaq)
-
- $3.88 USD
- 1.10 39.57%
-
Volume 22,740,301
-
AFTER HOURS 7:59 PM EDT 03/21/17
- $3.84 -0.04 -1.03%
-
AFTER HOURS Vol 103,666
- Volume 22,740,301
- 65 Day Avg Vol 4,501,833
- 1 Day Range 2.7734 - 4.10
- 52 Week Range 0.502 - 6.98
- Compare to Benchmark:
- DJIA
- S&P 500
- GLOBAL DOW
- NASDAQ
- Health Care/Life Sciences
- Open 2.83
- Prior Close 2.78
- 1 Day
- PULM 39.57%
- DJIA -1.14%
- Russell 2K -2.71%
- Health Care/Life Sciences -0.04%
News Pulmatrix Inc.PULM
- Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology
- Press Release
- Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline
- Press Release
- Technical Reports on Biotech Stocks -- Bioverativ, Pulmatrix, PharmAthene, and Zosano Pharma
- Press Release
- The Biotech Market Grows as Demand for New Therapeutics Increases
- Press Release
- Pulmatrix Announces Over $3.0 Million Registered Direct Offering
- Press Release
- Pulmatrix Announces $5 Million Registered Direct Offering
- Press Release
- Pulmatrix Drug Candidate Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
- Press Release
Key Stock Data
?
- P/E Ratio (TTM)
- The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
- Earnings Per Share (TTM)
- A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
- Market Capitalization
- Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
- Shares Outstanding
- Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
- Public Float
- The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
- Dividend Yield
- A company's dividend expressed as a percentage of its current stock price.
Key Stock Data
-
P/E Ratio (TTM)
N/A -
EPS (TTM)
$-1.87 -
Market Cap
$49.57 M -
Shares Outstanding
16.85 M -
Public Float
8.69 M -
Yield
PULM has not issued dividends in more than 1 year. -
Latest Dividend
N/A -
Ex-Dividend Date
N/A
?
- Shares Sold Short
- The total number of shares of a security that have been sold short and not yet repurchased.
- Change from Last
- Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
- Percent of Float
- Total short positions relative to the number of shares available to trade.
Short Interest (02/28/17)
-
Shares Sold Short
1.00 M -
Change from Last
-29.77% -
Percent of Float
11.57%
?
- Money Flow Uptick/Downtick Ratio
- Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.
Stock Money Flow
-
Uptick/Downtick Trade Ratio
Net Money Flow ($)
-259,810Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
Advertisement
Competitors PULM
| Company | Change | P/E (TTM) |
|---|---|---|
REGNRegeneron Pharmaceuticals Inc. | -2.89% | 48.81 |
NKTRNektar Therapeutics | -1.27% | - |
GLYCGlycoMimetics Inc. | -8.11% | - |
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and...
- Employees -Sector Biotechnology
- Sales or Revenue 835,000Industry Health Care/Life Sciences
- 1Y Sales Change -30.47%Fiscal Year Ends December 31 Download Reports
- Mark T. Iwicki Chairman
- Robert W. Clarke President, Chief Executive Officer & Director
- William E. Duke Chief Financial Officer, Treasurer & Secretary
- David L. Hava Chief Scientific Officer
Research & Ratings Pulmatrix Inc.PULM
Per-Share Earnings, Actuals and Estimates
| Q1 2017 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Q2 2017 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
Net Income
| Dec 2016 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | -116.71% | | ||||||||||
| Sales or Revenue | 117,000 | | ||||||||||
| Sales or Revenue Growth | -57.45% | | ||||||||||
| EBITDA | -4.43 M | | ||||||||||
| 2016 | 5-year trend | |||||||||||
| Net Income Growth | -6.41% | | ||||||||||
| Sales or Revenue | 835,000 | | ||||||||||
| Sales or Revenue Growth | -30.47% | | ||||||||||
| EBITDA | -17.08 M | |